As of 2026-03-31, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 477.44 mil USD. SAGE's TTM EBITDA according to its financial statements is -294.68 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 14.3x | 14.2x |
| Forward P/E multiples | 17.5x - 21.1x | 19.8x |
| Fair Price | (81.16) - (65.86) | (78.72) |
| Upside | -1035.0% - -858.7% | -1006.9% |
| Date | EV/EBITDA |